Literature DB >> 29447953

Dendrite growth and the effect of ectopic Rheb expression on cortical neurons.

Aidan M Sokolov1, Caitlin M Seluzicki2, Mary C Morton3, David M Feliciano4.   

Abstract

Ras homology enriched in brain (Rheb) is a GTPase that activates the protein kinase mammalian Target of Rapamycin (mTOR). Rheb mutations cause intellectual delay and megalencephaly. mTOR hyperactivation causes a constellation of neurodevelopmental disorders called "mTOR-opathies" that are frequently accompanied by hyperexcitable cortical malformations. Cortical malformations within the anterior cingulate cortex (ACC) and somatosensory cortex (SSC) frequently colocalize with hyperexcitability. Although Rheb and mTOR are implicated in the formation of cortical lesions, seizure activity, and defects in neuronal migration, the contribution of Rheb to changes in neuron size and dendrite morphology is not well established. Here, in utero electroporation of the developing embryonic brain was used to assess soma and dendrite growth in ACC and SCC layer II/III neurons. We found that between P0 and P21, neuronal soma size increased by 50 and 122 percent in the ACC and SSC, respectively. The increased size was accompanied by an increase in the number of basal dendrites and enhanced dendrite complexity. As an indicator of the involvement of the mTOR pathway in neuron maturation, phosphorylation of the mammalian target of rapamycin (mTOR) substrate S6 was identified in migrating cortical neuroblasts and maturing neurons. Notably, ectopic expression of Rheb caused cortical malformations comprised of ectopically positioned cytomegalic neurons with dendrite hypertrophy. This study provides a direct comparison of neuron maturation across two cortical regions during development, provides evidence for mTOR pathway activity during neuron maturation, and demonstrates that ectopic Rheb expression without mutation is sufficient to induce cortical malformations with cytomegaly and dendrite hypertrophy.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Dendrite; Focal cortical dysplasia; Rheb; mTOR

Mesh:

Substances:

Year:  2018        PMID: 29447953      PMCID: PMC5889745          DOI: 10.1016/j.neulet.2018.02.021

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  54 in total

Review 1.  mTOR signaling in epilepsy: insights from malformations of cortical development.

Authors:  Peter B Crino
Journal:  Cold Spring Harb Perspect Med       Date:  2015-04-01       Impact factor: 6.915

Review 2.  Molecular neurobiology of mTOR.

Authors:  Katarzyna Switon; Katarzyna Kotulska; Aleksandra Janusz-Kaminska; Justyna Zmorzynska; Jacek Jaworski
Journal:  Neuroscience       Date:  2016-11-23       Impact factor: 3.590

3.  Tuberous sclerosis: a Golgi study of cortical tuber.

Authors:  I Ferrer; I Fabregues; J Coll; T Ribalta; A Rives
Journal:  Clin Neuropathol       Date:  1984 Mar-Apr       Impact factor: 1.368

4.  Normalizing translation through 4E-BP prevents mTOR-driven cortical mislamination and ameliorates aberrant neuron integration.

Authors:  Tiffany V Lin; Lawrence Hsieh; Tomoki Kimura; Taylor J Malone; Angélique Bordey
Journal:  Proc Natl Acad Sci U S A       Date:  2016-09-19       Impact factor: 11.205

5.  Cytoarchitectural alterations are widespread in cerebral cortex in tuberous sclerosis complex.

Authors:  Leah Marcotte; Eleonora Aronica; Marianna Baybis; Peter B Crino
Journal:  Acta Neuropathol       Date:  2012-02-11       Impact factor: 17.088

6.  Familial cortical dysplasia caused by mutation in the mammalian target of rapamycin regulator NPRL3.

Authors:  Joe C Sim; Thomas Scerri; Miriam Fanjul-Fernández; Jessica R Riseley; Greta Gillies; Kate Pope; Hanna van Roozendaal; Julian I Heng; Simone A Mandelstam; George McGillivray; Duncan MacGregor; Lakshminarayanan Kannan; Wirginia Maixner; A Simon Harvey; David J Amor; Martin B Delatycki; Peter B Crino; Melanie Bahlo; Paul J Lockhart; Richard J Leventer
Journal:  Ann Neurol       Date:  2015-12-12       Impact factor: 10.422

7.  Cell-specific alterations of glutamate receptor expression in tuberous sclerosis complex cortical tubers.

Authors:  Delia M Talos; David J Kwiatkowski; Kathia Cordero; Peter M Black; Frances E Jensen
Journal:  Ann Neurol       Date:  2008-04       Impact factor: 10.422

8.  Rheb is a direct target of the tuberous sclerosis tumour suppressor proteins.

Authors:  Yong Zhang; Xinsheng Gao; Leslie J Saucedo; Binggen Ru; Bruce A Edgar; Duojia Pan
Journal:  Nat Cell Biol       Date:  2003-06       Impact factor: 28.824

9.  Impaired Reelin-Dab1 Signaling Contributes to Neuronal Migration Deficits of Tuberous Sclerosis Complex.

Authors:  Uk Yeol Moon; Jun Young Park; Raehee Park; Jennifer Y Cho; Lucinda J Hughes; James McKenna; Laura Goetzl; Seo-Hee Cho; Peter B Crino; Michael J Gambello; Seonhee Kim
Journal:  Cell Rep       Date:  2015-07-30       Impact factor: 9.423

10.  Convulsive seizures from experimental focal cortical dysplasia occur independently of cell misplacement.

Authors:  Lawrence S Hsieh; John H Wen; Kumiko Claycomb; Yuegao Huang; Felicia A Harrsch; Janice R Naegele; Fahmeed Hyder; Gordon F Buchanan; Angelique Bordey
Journal:  Nat Commun       Date:  2016-06-01       Impact factor: 14.919

View more
  9 in total

1.  Dynamic analysis of 4E-BP1 phosphorylation in neurons with Tsc2 or Depdc5 knockout.

Authors:  Philip H Iffland; Allan E Barnes; Marianna Baybis; Peter B Crino
Journal:  Exp Neurol       Date:  2020-08-08       Impact factor: 5.330

2.  Heterogeneity and excitability of BRAFV600E-induced tumors is determined by Akt/mTOR-signaling state and Trp53-loss.

Authors:  Silvia Cases-Cunillera; Karen M J van Loo; Julika Pitsch; Anne Quatraccioni; Sugirthan Sivalingam; Paolo Salomoni; Valeri Borger; Dirk Dietrich; Susanne Schoch; Albert J Becker
Journal:  Neuro Oncol       Date:  2022-05-04       Impact factor: 13.029

Review 3.  Role of mTOR Complexes in Neurogenesis.

Authors:  Francesca LiCausi; Nathaniel W Hartman
Journal:  Int J Mol Sci       Date:  2018-05-22       Impact factor: 5.923

Review 4.  The Ras Superfamily of Small GTPases in Non-neoplastic Cerebral Diseases.

Authors:  Liang Qu; Chao Pan; Shi-Ming He; Bing Lang; Guo-Dong Gao; Xue-Lian Wang; Yuan Wang
Journal:  Front Mol Neurosci       Date:  2019-05-21       Impact factor: 5.639

5.  Long-Term Therapeutic Efficacy of Intravenous AAV-Mediated Hamartin Replacement in Mouse Model of Tuberous Sclerosis Type 1.

Authors:  Shilpa Prabhakar; Pike See Cheah; Xuan Zhang; Max Zinter; Maria Gianatasio; Eloise Hudry; Roderick T Bronson; David J Kwiatkowski; Anat Stemmer-Rachamimov; Casey A Maguire; Miguel Sena-Esteves; Bakhos A Tannous; Xandra O Breakefield
Journal:  Mol Ther Methods Clin Dev       Date:  2019-08-16       Impact factor: 6.698

6.  The amino acid transporter Slc7a5 regulates the mTOR pathway and is required for granule cell development.

Authors:  Aidan M Sokolov; Jennie C Holmberg; David M Feliciano
Journal:  Hum Mol Genet       Date:  2020-11-04       Impact factor: 6.150

7.  Gene therapy for tuberous sclerosis complex type 2 in a mouse model by delivery of AAV9 encoding a condensed form of tuberin.

Authors:  Pike-See Cheah; Shilpa Prabhakar; David Yellen; Roberta L Beauchamp; Xuan Zhang; Shingo Kasamatsu; Roderick T Bronson; Elizabeth A Thiele; David J Kwiatkowski; Anat Stemmer-Rachamimov; Bence György; King-Hwa Ling; Masao Kaneki; Bakhos A Tannous; Vijaya Ramesh; Casey A Maguire; Xandra O Breakefield
Journal:  Sci Adv       Date:  2021-01-08       Impact factor: 14.136

8.  Corrigendum: Convergent and Divergent Mechanisms of Epileptogenesis in mTORopathies.

Authors:  Lena H Nguyen; Angélique Bordey
Journal:  Front Neuroanat       Date:  2021-07-06       Impact factor: 3.856

9.  Persistent Rheb-induced mTORC1 activation in spinal cord neurons induces hypersensitivity in neuropathic pain.

Authors:  Xiaqing Ma; Wenjie Du; Wenying Wang; Limin Luo; Min Huang; Haiyan Wang; Raozhou Lin; Zhongping Li; Haibo Shi; Tifei Yuan; Wei Jiang; Paul F Worley; Tao Xu
Journal:  Cell Death Dis       Date:  2020-09-12       Impact factor: 8.469

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.